Page tree
Skip to end of metadata
Go to start of metadata


August 14th, 2020


12:30pm - 1:15pm 


ACS CAN → Kelly Durden, Devon Adams

MITRE → Caroline Potteiger, Salim Semy, Zach Lister, Michelle Casagni 

Cancer Insights → Tarun Kumar, Shilpa Mahatma, Sharon Alford → Elly Cohen

TrialScope →

Action items

  • All → take a look at the Trial Matching contact list and let Caroline know of any missing organizations. 
  • All → please create a Confluence account and let Caroline know when you do. Here is the link -
  • All → brainstorm ways to recruit patients for the Phase 1A study. 
  • Salim → send Elly IRB study proposal. 

Discussion notes in blueDecisions in greenAction items in red.

Planned Agenda Topics

  • <Hold for hot topics from project team>
  • Update on ACS CAN membership? 
    • No updates. 
  • Engagement Update
    • UCSF → Elly meeting with Adam and Leslie August 17th. 
    • UTSW → met with UTSW on Wednesday and will be following up next week. 
    • Massive Bio → Seline will be looking into what's needed to send over patient data for the minimal eligibility criteria. 
    • Trialjectory → will be discussing their timeline for working on a project like this and will get back to us. 
    • Flatiron → will be discussing internally what's needed to send over patient data. 
    • NCI → meeting on August 17th. 
    • Other updates?
  • Public Call 
    • Caroline created a list of all the orgs we've talked to about this project so we can send out a personalized email to them. 
    • Any additions to the list? 
  • Confluence
  • Phase 1A Planning (continued) 
    • Please use this link to see project planning - Phase 1A Tasks 
      • Notes were taken on the Trial Matching - 1A Tasks page. 
    • One of the goals for Phase 1A is to create a working version of this project so when health systems and other organizations would like to join, there is a low barrier of entry. 
    • Could potentially list this study on 
    • We should include all types of trials in Phase 1A. This could be interventional for treatment and/or symptoms, interventional for quality of life, or observational. 
      • With the current demo, trial type is designated by 
    • The type of patient who would join this phase of the study is probably a patient who is highly motivated to find a clinical trial. 
      • There are many myths that cause patients to not join clinical trials.

  • No labels